miR-497-5p inhibits gastric cancer cell proliferation and growth through targeting PDK3

Abstract

MicroRNA plays an important role in gastric cancer (GC) development, while the function of miR-497-5p in this disease remains unknown. In the present study, we demonstrated miR-497-5p as a tumor suppressive microRNA in GC. miR-497-5p was down-regulated in GC tissues and its expression was associated with the disease stage. Inhibition of miR-497-5p promoted GC cell proliferation and growth. By contrast, miR-497-5p ectopic expression suppressed the proliferation and growth of GC cells. In addition, miR-497-5p inhibited DNA synthesis and enhanced apoptosis in GC cells. The cell cycle progression was suppressed by miR-497-5p. Mechanistically, miR-497-5p directly targeted and suppressed the expression of pyruvate dehydrogenase kinase 3 (PDK3), which is highly expressed in GC tissues. Over-expression of PDK3 promoted the proliferation of GC cells. Our study revealed that miR-497-5p inhibited GC cell proliferation and growth via targeting PDK3.

CASC9 Facilitates Cell Proliferation in Bladder Cancer by Regulating CBX2 Expression

“…3b). Meanwhile, miR-497-5p has been reported to have suppressive effect on multiple human malignancies [24, 25], and we finally chose miR-497-5p for further exploration. The expression of miR-497-5p was notably enhanced by transfection of miR-497-5p mimics (Fig.…”

Regulation of microRNA‑497 expression in human cancer (Review)

“…Subsequently, a study of the global miRNA expression profile of gastric cancer was the first to demonstrate that the expression of miR-497 was increased in non-tumor tissues (12). Accumulating evidence shows that the expression of miR-497 is downregulated in several tumor types, including primary peritoneal carcinoma (13), adrenocortical carcinoma (14,15), malignant astrocytoma (16), colorectal cancer (17)(18)(19)(20)(21), osteosarcoma (22), cervical cancer (23), liver cancer (24)(25)(26)(27)(28), breast cancer (29)(30)(31), neuroblastoma (32), non-small cell lung cancer (33)(34)(35), gastric cancer (36)(37)(38), ovarian cancer (39), nasopharyngeal carcinoma (40), osteosarcoma (41,42), angiosarcoma (43), cervical…”

“…Subsequently, a study of the global miRNA expression profile of gastric cancer was the first to demonstrate that the expression of miR-497 was increased in non-tumor tissues ( 12 ). Accumulating evidence shows that the expression of miR-497 is downregulated in several tumor types, including primary peritoneal carcinoma ( 13 ), adrenocortical carcinoma ( 14 , 15 ), malignant astrocytoma ( 16 ), colorectal cancer ( 17 – 21 ), osteosarcoma ( 22 ), cervical cancer ( 23 ), liver cancer ( 24 – 28 ), breast cancer ( 29 – 31 ), neuroblastoma ( 32 ), non-small cell lung cancer ( 33 – 35 ), gastric cancer ( 36 – 38 ), ovarian cancer ( 39 ), nasopharyngeal carcinoma ( 40 ), osteosarcoma ( 41 , 42 ), angiosarcoma ( 43 ), cervical cancer ( 44 , 45 ), thyroid cancer ( 46 , 47 ), cutaneous squamous cell carcinoma ( 48 , 49 ), melanoma ( 50 ), glioma ( 51 ), clear cell renal cell carcinoma ( 52 ), anaplastic large cell lymphoma ( 53 ), esophageal carcinoma ( 54 ) and bladder cancer ( 9 ), among others. These results suggest that miR-497 acts as a tumor suppressor.…”

DLX6‐AS1 accelerates cell proliferation through regulating miR‐497‐5p/SNCG pathway in prostate cancer

“…The expression status of top five candidate miRNAs was shown in Figure 3A, and the rest 10 candidate genes were illustrated in Figure S2. It was certified from previous researches that miR‐497‐5p inhibited the development of multiple carcinomas, 15,16 so miR‐497‐5p was chosen for subsequent explorations. As shown by RT‐qPCR analysis, the expression of miR‐497‐5p was consistently downregulated in PCa cell lines in contrast to normal prostate cell line WPMY1 (Figure 3B).…”

“…Previous researches implied that miR‐497‐5p ordinarily exerted suppressive effects in cancer progression. For instance, miR‐497‐5p suppresses cell proliferation by targeting PDK3 in gastric cancer 15 . MiR‐497‐5p inhibits the development of non‐small cell lung cancer by modulating FGF2 expression 16 .…”